Substance / Medication

Perampanel

Overview

Active Ingredient
perampanel
RxNorm CUI
1356552
Labeler: Sun Pharmaceutical Industries, Inc.Updated: 2025-12-19T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking perampanel ( 5.1). These reactions occurred in

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
0
Recruiting
5
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effectiveness and safety of perampanel in Lennox-Gastaut syndrome: a GRADE-assessed systematic review and meta-analysis.
Kumar Danisha, Sabet Haneen, Elshahat Amr et al. · Naunyn Schmiedebergs Arch Pharmacol · 2025
PMID: 40613940Meta-Analysis
Efficacy and safety of perampanel for the treatment of epilepsy in adolescents: a meta-analysis.
Wang Ting, Li Limin, Sun Fei et al. · Int J Neurosci · 2023
PMID: 35301936Meta-Analysis
Efficacy and safety of perampanel for epilepsy: a systematic review and meta-analysis of real-world studies.
Fan P-F, Zhuo C, Huang M · Eur Rev Med Pharmacol Sci · 2023
PMID: 37458642Meta-Analysis
The safety of perampanel in different disorders and doses: A meta-analysis.
Liu Ping, Zhu Zhongning, Wu Huizhen · Seizure · 2023
PMID: 36724644Meta-Analysis
Perampanel add-on for drug-resistant focal epilepsy.
Bresnahan Rebecca, Hill Ruaraidh A, Wang Jin · Cochrane Database Syst Rev · 2023
PMID: 37059702Meta-AnalysisFull text (PMC)
Efficacy and safety of perampanel in epilepsy: A systematic review and meta-analysis of randomised controlled trials.
Lavu Alekhya, Aboulatta Laila, Abou-Setta Ahmed M et al. · Seizure · 2022
PMID: 36206645Meta-Analysis
Perampanel in achieving status epilepticus cessation: A systematic review.
Perez Dominique Q, Espiritu Adrian I, Jamora Roland Dominic G · Epilepsy Behav · 2022
PMID: 35151187Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Perampanel (substance)
SNOMED CT
703127006
UMLS CUI
C2698764
RxNorm CUI
1356552
Labeler
Sun Pharmaceutical Industries, Inc.

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.